Sagility Ltd.
SAGILITYInformation Technology filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
9 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 9 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20241130 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250210 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250521 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250805 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251031 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260203 | 2025-12-31 | yes | |
| ANALYST_MEET | 20260402 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260515 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260728 | 2026-06-30 | yes |
SAGILITY
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 45.00 |
| 52-week range | 36.35 – 54.58 |
| Return 1M | 4.6% |
| Return 3M | 11.47% |
| Return 1Y | 3.88% |
| Return 3Y | not reported for this period |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,963.00 |
| Other income | 14.00 |
| Total income | 1,978.00 |
| Cost of materials consumed | 0.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | 0.00 |
| Employee benefit expense | 1,228.00 |
| Finance costs | 22.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.51 | 0.00 |
| institutions foreign | 0.10 | -0.00 |
| institutions domestic | 0.21 | -0.01 |
| mutual funds | 0.13 | -0.01 |
| public | 0.49 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| ANALYST_MEET | 2026-03-31 | 1 |
| TRANSCRIPT | 2026-06-30 | 8 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,325.00 | 1,453.00 | 1,568.00 | 1,539.00 | 1,658.00 | 1,971.00 | 2,024.00 | 1,963.00 |
| Other income | 15.00 | 44.00 | 10.00 | 10.00 | 58.00 | 8.00 | 25.00 | 14.00 |
| Total income | 1,340.00 | 1,497.00 | 1,579.00 | 1,549.00 | 1,717.00 | 1,980.00 | 2,049.00 | 1,978.00 |
| Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee benefit expense | 812.00 | 862.00 | 974.00 | 987.00 | 1,027.00 | 1,219.00 | 1,277.00 | 1,228.00 |
| Finance costs | 30.00 | 30.00 | 30.00 | 27.00 | 25.00 | 25.00 | 22.00 | 22.00 |
| Depreciation and amortisation | 126.00 | 116.00 | 114.00 | 118.00 | 122.00 | 124.00 | 124.00 | 128.00 |
| Other expenses | 211.00 | 199.00 | 221.00 | 206.00 | 216.00 | 241.00 | 263.00 | 298.00 |
| Total expenses | 1,180.00 | 1,207.00 | 1,340.00 | 1,338.00 | 1,390.00 | 1,608.00 | 1,686.00 | 1,675.00 |
| Profit before exceptional items and tax | 160.00 | 290.00 | 239.00 | 210.00 | 327.00 | 371.00 | 363.00 | 303.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.00 | 0.00 | -15.00 |
| Profit before tax | 160.00 | 290.00 | 239.00 | 210.00 | 327.00 | 339.00 | 363.00 | 287.00 |
| Current tax | 50.00 | 99.00 | 72.00 | 83.00 | 95.00 | 88.00 | 81.00 | 89.00 |
| Deferred tax | -7.00 | -26.00 | -16.00 | -21.00 | -19.00 | -17.00 | 24.00 | -18.00 |
| Tax expense | 43.00 | 73.00 | 56.00 | 62.00 | 76.00 | 71.00 | 105.00 | 71.00 |
| Profit for the period | 117.00 | 217.00 | 183.00 | 149.00 | 251.00 | 268.00 | 258.00 | 217.00 |
| Profit attributable to owners | — | 217.00 | 183.00 | 149.00 | 251.00 | 268.00 | 258.00 | 217.00 |
| Profit attributable to non-controlling interests | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other comprehensive income | 81.00 | 62.00 | 32.00 | -0.00 | 145.00 | 57.00 | 208.00 | 45.00 |
| Total comprehensive income | 198.00 | 279.00 | 215.00 | 148.00 | 396.00 | 325.00 | 465.00 | 261.00 |
| Earnings per share, basic | 0.25 | 0.46 | 0.39 | 0.32 | 0.53 | 0.57 | 0.56 | 0.46 |
| Earnings per share, diluted | 0.25 | 0.46 | 0.39 | 0.32 | 0.53 | 0.57 | 0.56 | 0.46 |
Annual results, as filed
| Line | 2025-03-31 | 2026-03-31 |
|---|---|---|
| Revenue from operations | 5,570.00 | 7,193.00 |
| Other income | 56.00 | 98.00 |
| Total income | 5,626.00 | 7,291.00 |
| Cost of materials consumed | 0.00 | 0.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 |
| Employee benefit expense | 3,499.00 | 4,510.00 |
| Finance costs | 127.00 | 99.00 |
| Depreciation and amortisation | 467.00 | 487.00 |
| Other expenses | 773.00 | 922.00 |
| Total expenses | 4,866.00 | 6,019.00 |
| Profit before exceptional items and tax | 760.00 | 1,272.00 |
| Exceptional items | 0.00 | -33.00 |
| Profit before tax | 760.00 | 1,239.00 |
| Current tax | 263.00 | 346.00 |
| Deferred tax | -42.00 | -32.00 |
| Tax expense | 221.00 | 314.00 |
| Profit for the period | 539.00 | 925.00 |
| Profit attributable to owners | 539.00 | 925.00 |
| Profit attributable to non-controlling interests | — | 0.00 |
| Other comprehensive income | 104.00 | 409.00 |
| Total comprehensive income | 643.00 | 1,334.00 |
| Earnings per share, basic | 1.17 | 1.98 |
| Earnings per share, diluted | 1.17 | 1.98 |
Balance sheet, as filed
| Line | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|
| Total assets | 10,630.00 | 11,051.00 | 11,527.00 | 12,601.00 |
| Non-current assets | 8,810.00 | 9,230.00 | 9,314.00 | 9,657.00 |
| Current assets | 1,820.00 | 1,821.00 | 2,213.00 | 2,945.00 |
| Property, plant and equipment | 911.00 | 922.00 | 893.00 | 910.00 |
| Capital work-in-progress | 0.00 | 0.00 | 0.00 | 39.00 |
| Goodwill | 5,709.00 | 6,039.00 | 6,167.00 | 6,405.00 |
| Other intangible assets | 1,937.00 | 2,036.00 | 2,016.00 | 2,037.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Trade receivables | 1,058.00 | 1,267.00 | 1,422.00 | 1,839.00 |
| Cash and cash equivalents | 507.00 | 344.00 | 292.00 | 358.00 |
| Total equity and liabilities | 10,630.00 | 11,051.00 | 11,527.00 | 12,601.00 |
| Equity | 7,816.00 | 8,336.00 | 8,894.00 | 9,659.00 |
| Equity share capital | 4,679.00 | 4,679.00 | 4,679.00 | 4,679.00 |
| Other equity | 3,137.00 | 3,657.00 | 4,215.00 | 4,980.00 |
| Total liabilities | 2,814.00 | 2,715.00 | 2,633.00 | 2,942.00 |
| Non-current liabilities | 1,735.00 | 1,626.00 | 1,431.00 | 1,044.00 |
| Current liabilities | 1,080.00 | 1,089.00 | 1,202.00 | 1,898.00 |
| Borrowings, non-current | 678.00 | 1,023.00 | 828.00 | 381.00 |
| Borrowings, current | 267.00 | 378.00 | 403.00 | 729.00 |
| Trade payables | 271.00 | 214.00 | 214.00 | 222.00 |
Cash flow, as filed
| Line | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|
| Net cash from operating activities | 609.00 | 1,214.00 | 559.00 | 1,203.00 |
| Net cash from investing activities | -436.00 | -964.00 | -372.00 | -711.00 |
| Net cash from financing activities | -11.00 | -256.00 | -247.00 | -501.00 |
| Purchase of property, plant and equipment | 68.00 | 124.00 | 81.00 | 192.00 |
| Net increase in cash | 163.00 | -0.00 | -52.00 | 14.00 |
| con:CFO.BEFORE_TAX | 687.00 | 1,387.00 | 743.00 | 1,576.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 78.00 | 173.00 | 184.00 | 373.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 2.00 | 0.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 376.00 | 858.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2024-11-12 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 82.39 | 82.39 | 82.39 | 67.38 | 0.67 | 0.51 | 0.51 | 0.51 |
| Domestic institutions | 6.30 | 7.25 | 7.48 | 14.06 | 0.15 | 0.21 | 0.22 | 0.21 |
| Mutual funds | — | — | — | 8.34 | 0.09 | 0.13 | 0.15 | 0.13 |
| Insurance companies | 1.09 | 0.80 | 0.91 | 3.13 | 0.03 | 0.04 | 0.04 | 0.04 |
| Foreign institutions | 6.90 | 3.78 | 3.39 | 5.99 | 0.06 | 0.10 | 0.10 | 0.10 |
| Public | 17.61 | 17.61 | 17.61 | 32.62 | 0.33 | 0.49 | 0.49 | 0.49 |
| Non-institutional | 4.40 | 6.58 | 6.74 | 12.58 | 0.12 | 0.17 | 0.17 | 0.18 |
| Shares outstanding | 4681328413 | 4681328413 | 4681328413 | 4681328413 | 4681328413 | 4681328413 | 4681328413 | 4681328413 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Sagility B.V. | Subsidiary | Any other transaction, Interest paid | 21,775,650,000.00 | 7 |
| Sagility LLC | Step down subsidiary | Any other transaction, Sale of goods or services | 16,753,080,000.00 | 6 |
| Sagility (US) Holdings Inc | Wholly owned subsidiary | Investment | 11,150,640,000.00 | 1 |
| Sagility (US) Inc. | Wholly owned subsidiary | Investment | 11,150,640,000.00 | 1 |
| Sagility (US) Holdings Inc. | Parent | Any other transaction | 11,150,640,000.00 | 2 |
| Sagility India Limited | Parent | Any other transaction, Purchase of goods or services | 8,089,110,000.00 | 4 |
| Sagility Philippines B.V. - Philippines Branch | Step down subsidiary | Any other transaction, Purchase of goods or services | 7,949,750,000.00 | 4 |
| Ramesh Gopalan | Key Managerial Remuneration | Remuneration | 3,318,250,000.00 | 1 |
| Sagility (Jamaica) Limited | Fellow subsidiary | Purchase of goods or services | 2,562,850,000.00 | 1 |
| Sagility Provider Solutions LLC | Step down subsidiary | Sale of goods or services | 2,037,640,000.00 | 3 |
| Sagility (Colombia) SAS | Fellow subsidiary | Purchase of goods or services | 181,430,000.00 | 2 |
| Sagility Employees Gratuity Trust | Post-employment benefit plans of t | Any other transaction | 39,130,000.00 | 2 |
| Sarvabhouman Doraiswamy Srinivasan | Key Managerial Remuneration | Remuneration | 28,070,000.00 | 1 |
| Sagility Technologies LLC | Fellow subsidiary | Purchase of goods or services | 8,410,000.00 | 1 |
| Smita V. Nair | Key Managerial Remuneration | Remuneration | 6,790,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-28 | Q1FY27 | Read the call | |
| 2026-05-15 | Q4FY26 | Read the call | |
| 2026-04-02 | Q4FY26 | Read the call | |
| 2026-02-03 | Q3FY26 | Read the call | |
| 2025-10-31 | Q2FY26 | Read the call | |
| 2025-08-05 | Q1FY26 | Read the call | |
| 2025-05-21 | Q4FY25 | Read the call | |
| 2025-02-10 | Q3FY25 | Read the call | |
| 2024-11-30 | Q2FY25 | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY26 | Q1FY27 | Q2FY25 | Q2FY26 | Q3FY25 | Q3FY26 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | — | — | On the balance sheet, our cash and bank balances as of the end of Q2 stood at ₹5,068 million and after payouts of the shareholder loan in the Q1. CapE… | — | And we had a CapEx spend for the nine months ended December at ₹1,122 million. | On this slide, you'll see the standard KPIs that we report on client concentration, capacity additions, grouping of clients by annual revenues, and so… | — | They are also looking at zero or no CapEx, no upfront spending. |
| Capital allocation | We've always said that our deep health care expertise and our continued investment in building new AI use cases accelerated with acquisition of BirchA… | Our CareSeed acquisition helps us on both these fronts, strengthening our capabilities in the quality area, especially for Medicare Advantage plans, a… | And as many of you know, Sagility was formed as a result of a carve out from the divestment that AGS did in the beginning of '22. | I'm also happy to announce that the Board has announced as approved, an interim dividend of 0.05 or 5 paise per share to be paid in Q3. So let me turn… | In addition, we announced the acquisition just last week. | Following the acquisition of BroadPath, it's likely to increase to 4.5%. | In addition, our focus on mid-market payer clients, both through organic growth and further accelerated by the recent acquisition of BroadPath continu… | As you can see if you look at the lifecycle of let's say a member, an insured who goes through the payer organisation all the way from member acquisit… |
| Costs | Our payer and provider clients continue to navigate heightened cost pressures as they contend with regulatory evolution policy changes. | So payers face mounting cost, workforce, and regulatory pressures. | And, with the mounting cost pressures, more and more of that work is being outsourced. | They wanted us to unlock further cost savings through next generation levels. | But even in times where they're under cost pressure, we both from virtue of the relationship and as well as the expectation of clients on us, we have … | Higher administrative throughput across engagement service volumes, prior authorisation, claims, and clinical workflows alongside continued cost press… | The industry is facing a lot of headwinds in terms of cost pressures, evolving regulatory frameworks and policy changes. | And in this part, like any other IT services, managed services deal, client outcomes are very clear that they are looking at cost savings committed, n… |
| Debt and cash | We continue to generate healthy cash flows to reimburse into capability building and digital transformation. | Overall, the quarter reflects the resilience of our business with strong growth, healthy profitability, strong cash generation, and an improved workin… | So that's the details I've shown in the cash flow slide. | The consistent optimisation of our capital structure, including steady debt repayments, continues to strengthen cash flows and support investments in … | What is more attractive here is the operating cash flow. | Ongoing reduction in debt continues to strengthen our cash flows and enable continued investment in technology and in our domain. | Our strong cash flows, our healthy balance sheet, and our focused capital allocation have provided us the flexibility to invest for the long-term valu… | So given that we're very close to deleveraging event in January of 2027, our cash accretion is what it is, how close are we to another M&A event? |
| Demand | But, we are reasonably confident that the low to mid-teens will happen, given the state of our pipeline and given what we know about the seasonality t… | Against this backdrop, demand continues to favour partners that combine deep healthcare domain expertise with operational scale, technology, analytics… | — | In addition, we are well positioned to support payers in their increased demand for automation led eligibility and enrolment validation. | — | On a second strategic lever, large end-to-end managed constructs, our pipeline continues to advance. | And we don't see any slowing down, of the deal pipeline because of the economic issues. | We did the entire mapping similar exercise looked at what are the value drivers, what are the important aspects that needs to be done, and we created … |
| Guidance | Looking ahead, we expect to sustain growth in the low to mid-teen in constant currency. | Importantly, these seasonal revenues are recurring, and we expect the usual uptick again in Q3 and Q4 of FY 2027. | And even this quarter, this margin has been possible because of operational efficiencies, both through tech-led initiatives and process improvements, … | Looking ahead, we expect to sustain organic growth in the low to mid-teens in constant currency. | Our financial performance has been consistent in the last few years, and we expect this trend to continue forward. | However, our ongoing conversations remain active and we anticipate these discussions will gather momentum once the AEP seasonal peaks subsides. | Our financial performance has been consistent in the last few years, and we expect this to continue going forward as well. | And we expect to take advantage of the Gen AI capabilities that they've embedded in their platforms. |
| Margin | On the profitability front, we delivered an adjusted EBITDA of ₹3,687 million or $43.2 million representing an year-on-year increase of 26.5%. | U.S. healthcare organisations continue to operate in an environment where margin protection, cost discipline, and medical utilisation management remai… | And our EBITDA margins over the last two, three years have been consistent between 24% and 25%. | Operating profitability remained robust with adjusted EBITDA at INR 4,352 million or $49.8 million representing a year-on-year increase of 25.6%. | This reflects an adjusted EBITDA margin of 31.4%. | A quick reminder, our adjusted EBITDA does not include other income and Forex gains. | This reflects an adjusted EBITDA of 25.8%. | In terms of financials, again we don't intend to get deeper into the financials, but in the Q&A session happy to answer questions, but if you look at … |
| People | Annualised attrition was stable at 26.6% in line with the trend that we saw last year. | While select payers have reported slightly improved or lower medical utilisation, the broader market continues to see pressure from rising utilisation… | Our total headcount is about 38,000 people out of which we have 2,000 clinicians. | Annualized attrition remains steady at 26.3%, and it's consistent with the last year's trend. | Now if you look at our people metrics, our total headcount at the end of the year stood at 39,595. | Annual attrition for the quarter remained steady at 22.8%. | We reported a total headcount of 39,409 at the end of the fiscal year. | We will talk about the Medicare not only Medicare but across the board we will talk about the increase in utilisation and the challenges that that pos… |
| Pricing | So the pricing pressures, like I've mentioned in the previous calls, the pricing pressures are increasing because, like you said, as the client's prof… | There were no pricing levers that we exercised, right? | We think, we can maintain similar pricing, similar margins at a client-by-client level. | You talked about difference in pricing between AI agents and FTE. | First is on your stated strategy that you would look to penetrate more into mid-tier Pharma companies as well as look to crack complex deals, probably… | And second, is on the pricing, which CMS has announced for the CY 2027 MA plans. | And also, if we were to look at the growth for this quarter, can you break that down between volume growth and pricing growth, especially the organic … | We are very open at this point in time with clients on multiple pricing constructs and we are willing to take risks to be able to deliver those effici… |
| Revenue growth | Reflecting a year-on-year growth of 25.8% in INR terms and 23.1% in constant currency. | Revenue for the quarter was INR 19,635 million, which represented a year-on-year growth of 27.6%, or 15.2% in constant currency. | With that, let me quickly jump, into the results for Q2. We are pleased to report that in Q2 FY '25, we registered a year-on-year growth of 21.1%, in … | Organic growth was also strong registering 16%, year-on-year growth in INR terms and 11.1% in constant currency. | We are pleased to report in Q3 FY '25, we registered a year-on-year growth of 15.3% in rupee terms and is 14% in constant currency terms. | This represents a year-on-year growth of 35.7% in INR and 29.1% in constant currency. | As you know, this is our third earnings call, since our IPO and we had guided to mid to teen revenue growth, and a 24% plus EBITDA margins. | Sagility Ltd. Investor & Analyst Day Transcript Wednesday, 25th March 2026 MANAGEMENT • Ramesh Gopalan - Group CEO and Managing Director • Srinivas Ma… |